Advanced Parkinson's DiseasePhase 3NCT00335153
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
A Phase 3 study testing Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump and PEG tube in people with Advanced Parkinson's Disease, run by AbbVie (prior sponsor, Abbott) at 83 sites in 16 countries.
Trial summary
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Advanced Parkinson's Disease
- What is being tested?
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump and PEG tube
- Type of treatment
- Pill or oral medicine, Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 354 participants
- Where
- 83 sitesin 16 countries
- Study dates
- Jan 2008to Jun 2012
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
- Levodopa-responsive with severe motor fluctuations
- Recognizable off and on state (motor fluctuations) confirmed by diary
Who cannot join
- Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
- Undergone surgery for the treatment of PD
- Contraindications to levodopa (such as narrow angle glaucoma)
Trial locations and contacts
83 sites in 16 countries.
83 sites in 16 countries
United States31 sites
Site Reference ID/Investigator# 50062
Augusta, Georgia, 30912
Site Reference ID/Investigator# 50080
Baltimore, Maryland, 21201
Site Reference ID/Investigator# 50074
Baltimore, Maryland, 21287
Site Reference ID/Investigator# 50065
Birmingham, Alabama, 35222
Site Reference ID/Investigator# 50077
Bradenton, Florida, 34205
Site Reference ID/Investigator# 50058
Burlington, Vermont, 05401
Site Reference ID/Investigator# 50050
Chicago, Illinois, 60611
Site Reference ID/Investigator# 50078
Chicago, Illinois, 60612
Site Reference ID/Investigator# 50043
Cincinnati, Ohio, 45267
Site Reference ID/Investigator# 50044
Cleveland, Ohio, 44195-0001
Site Reference ID/Investigator# 50061
Englewood, Colorado, 80113
Site Reference ID/Investigator# 50060
Fort Lauderdale, Florida, 33308
Site Reference ID/Investigator# 50059
Fountain Valley, California, 92708
Site Reference ID/Investigator# 50049
Gainesville, Florida, 32610
Site Reference ID/Investigator# 50047
Jacksonville, Florida, 32209
Site Reference ID/Investigator# 50045
Kirkland, Washington, 98034
Site Reference ID/Investigator# 50064
Lexington, Kentucky, 40536
Site Reference ID/Investigator# 50048
Los Angeles, California, 90033
Site Reference ID/Investigator# 50072
Manhasset, New York, 11030
Site Reference ID/Investigator# 50070
Milwaukee, Wisconsin, 53226
Site Reference ID/Investigator# 50067
New York, New York, 10029
Site Reference ID/Investigator# 50066
New York, New York, 10032
Site Reference ID/Investigator# 50076
Oceanside, California, 92056
Site Reference ID/Investigator# 50042
Omaha, Nebraska, 68198-2045
Site Reference ID/Investigator# 50068
Port Charlotte, Florida, 33890
Site Reference ID/Investigator# 50069
Raleigh, North Carolina, 27607
Site Reference ID/Investigator# 50075
Shreveport, Louisiana, 71103
Site Reference ID/Investigator# 50073
St Louis, Missouri, 63110
Site Reference ID/Investigator# 50046
Tampa, Florida, 33613
Site Reference ID/Investigator# 50079
Washington D.C., District of Columbia, 20007
Site Reference ID/Investigator# 50063
Winston-Salem, North Carolina, 27157
Germany7 sites
Site Reference ID/Investigator# 48028
Berlin, 12200
Site Reference ID/Investigator# 48029
Berlin, 13088
Site Reference ID/Investigator# 48036
Freiburg im Breisgau, 79106
Site Reference ID/Investigator# 48034
Göttingen, 37075
Site Reference ID/Investigator# 48022
Hanau, 63450
Site Reference ID/Investigator# 48024
Hanover, 30625
Site Reference ID/Investigator# 48035
Mainz, 55131
Italy6 sites
Site Reference ID/Investigator# 50131
Arcugnano, 36057
Site Reference ID/Investigator# 50132
Catania, 95125
Site Reference ID/Investigator# 50128
Genoa, 16132
Site Reference ID/Investigator# 50129
Lido di Camaiore, 55043
Site Reference ID/Investigator# 50130
Naples, 80131
Site Reference ID/Investigator# 50127
Rome, 00163
Russia6 sites
Site Reference ID/Investigator# 50143
Kazan', 420061
Site Reference ID/Investigator# 50141
Moscow, 125367
Site Reference ID/Investigator# 50145
Saint Petersburg, 193312
Site Reference ID/Investigator# 50142
Saint Petersburg, 194044
Site Reference ID/Investigator# 50147
Saint Petersburg, 197089
Site Reference ID/Investigator# 50146
Saint Petersburg, 197706
Czechia5 sites
Site Reference ID/Investigator# 46436
Brno, 65691
Site Reference ID/Investigator# 46438
Hradec Králové, 500 05
Site Reference ID/Investigator# 46435
Pardubice, 532 03
Site Reference ID/Investigator# 46437
Prague, 128 08
Site Reference ID/Investigator# 46439
Prague, 15006
Spain5 sites
Site Reference ID/Investigator# 50154
Barcelona, 08003
Site Reference ID/Investigator# 50152
Barcelona, 08025
Site Reference ID/Investigator# 50202
Barcelona, 08035
Site Reference ID/Investigator# 50155
Barcelona, 08036
Site Reference ID/Investigator# 50153
Madrid, 28034
New Zealand4 sites
Site Reference ID/Investigator# 50126
Auckland, 1010
Site Reference ID/Investigator# 50123
Christchurch, 8011
Site Reference ID/Investigator# 50124
Hamilton, 3204
Site Reference ID/Investigator# 50125
Wellington, 6002
Portugal4 sites
Site Reference ID/Investigator# 50136
Almada, 2805-267
Site Reference ID/Investigator# 50134
Coimbra, 3000-075
Site Reference ID/Investigator# 50135
Lisbon, 1649-035
Site Reference ID/Investigator# 50137
Porto, 4200-319
Australia3 sites
Site Reference ID/Investigator# 46429
Adelaide, 5000
Site Reference ID/Investigator# 46427
Heidelberg, 3084
Site Reference ID/Investigator# 46425
Westmead, 2145
Canada3 sites
Site Reference ID/Investigator# 54545
Edmonton, T6G 2B7
Site Reference ID/Investigator# 46433
Montreal, H2L 4M1
Site Reference ID/Investigator# 46434
Toronto, M5T 2S8
Poland2 sites
Site Reference ID/Investigator# 50140
Lodz, 93-113
Site Reference ID/Investigator# 50139
Poznan, 61-485
Thailand2 sites
Site Reference ID/Investigator# 50150
Bangkok, 10330
Site Reference ID/Investigator# 50151
Bangkok, 10700
United Kingdom2 sites
Site Reference ID/Investigator# 50149
Liverpool, L9 7LJ
Site Reference ID/Investigator# 50148
London, WC1N 3BG
About this study
Official title: An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.
Read the detailed description
The study was composed of a screening period followed by 3 sequential on-treatment periods, as follows:
- Screening Period (up to 28 days): determination of eligibility and discontinuation of antiparkinsonian disease medications other than levodopa-carbidopa immediate release (LC-oral) prior to nasojejunal (NJ) tube placement.
- NJ Test Period (2 to 14 days): first hospitalization period, Baseline assessments, placement of NJ tube, and optimization of levodopa-carbidopa intestinal gel (LCIG) treatment via NJ tube and infusion pump (participant was hospitalized for NJ tube placement but hospitalization was not required for entire duration of LCIG treatment optimization).
- PEG-J Period (2 to 14 days): second hospitalization period; placement of PEG-J tube; further optimization of LCIG treatment.
- Post PEG-J Long-Term Treatment Period (Day 28 to Day 378): LCIG administration via a permanent PEG-J tube and infusion pump, with dosage adjusted according to clinical condition.
- Conditions
- Advanced Parkinson's Disease
- Being tested
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Keywords
- severe motor fluctuations, levodopa, levodopa/carbidopa intestinal gel, efficacy, dyskinesia, Parkinson's Disease, carbidopa, DUOPA
- Medical subject headings
- Dyskinesias, Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Levodopa-carbidopa intestinal gelDrug
Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
CADD-Legacy® 1400 ambulatory infusion pumpDevice
PEG tubeDevice
percutaneous endoscopic gastrostomy tube
J-tubeDevice
jejunal tube
| Study group | Role | What they receive |
|---|---|---|
| Levodopa-Carbidopa Intestinal Gel (LCIG) | Experimental | All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.
The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances. Receives: Drug: Levodopa-carbidopa intestinal gel; Device: CADD-Legacy® 1400 ambulatory infusion pump; Device: PEG tube; Device: J-tube |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs
AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.
Measured: Screening through Day 378 + 30 days
Number of Participants With Device Complications During the Nasojejunal (NJ) Test Period
Complications of the infusion device were collected during the NJ Test period. Pump, intestinal tube, NJ tube, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.
Measured: NJ Test Period (from 2 to 14 days)
Number of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods
Complications of the infusion device were collected during the PEG-J Surgery and Post-PEG Long-Term Treatment periods. Pump, PEG-J, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.
Measured: PEG-J Surgery Period (from 2 to 14 days) through the Long Term Treatment Period (Day 28 to Day 378)
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
Potentially clinically significant values for red blood cells (RBCs), hemoglobin, and hematocrit are specified for females (f) and males (m) separately in the category rows.
Measured: Screening through Day 378
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
Terms abbreviated in the table include aspartate aminotransferase (AST), upper limit of normal (ULN), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), female (f), and male (m).
Measured: Screening through Day 378
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.
Measured: up to 56 weeks
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.
Measured: Screening through Day 378
Number of Participants With Sleep Attacks at Baseline
To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.
Measured: Baseline
Number of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period
To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.
Measured: During the Post-PEG Long-Term Treatment Period (Day 28 through Day 378)
Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period
The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
Measured: Baseline, during the Post-PEG Long-term Treatment Period (Day 28 through Day 378)
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint
The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions regarding issues with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia [involuntary muscle movement]).
Measured: Baseline, Endpoint (last Post-PEG Long-Term Period visit up to Day 378)
Number of Participants With Confirmed Cases of Melanoma
A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination or end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.
Measured: Screening up to Day 378
Number of Participants Taking at Least 1 Concomitant Medication During the Study
Concomitant medications include those started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.
Measured: Screening up to Day 378
Secondary outcomes (21)
Change From Baseline in Average Daily "Off" Time at Endpoint
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Endpoint
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint
The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint
The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state'.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint
The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (Range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.
Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2006 (estimated)
- Study startJan 2008
- Primary completionJun 2012
- Study completionJun 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Advanced Parkinson's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 354 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Quintiles, Inc.
- Responsible party
- Sponsor
- Investigators
- Janet Benesh, Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00335153
- Sponsor's protocol ID
- S187.3.004
- Other IDs
- 2006-005186-18
- Status last verified
- Jan 2015
- First submitted
- 8 Jun 2006
- Last updated
- 16 Jan 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14.
PubMed 26777085Lew MF, Slevin JT, Kruger R, Martinez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul;21(7):742-8. doi: 10.1016/j.parkreldis.2015.04.022. Epub 2015 Apr 28.
PubMed 25962554Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.
PubMed 25545465
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications
- ClinicalTrials.gov ID
- NCT00335153
- Acronym / sponsor ID
- S187.3.004
- Conditions
- Advanced Parkinson's Disease
- Keywords
- severe motor fluctuations, levodopa, levodopa/carbidopa intestinal gel, efficacy, dyskinesia, Parkinson's Disease, carbidopa, DUOPA
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 354 participants (actual)
- Lead sponsor
- AbbVie (prior sponsor, Abbott)Industry (pharma, biotech, devices)
- Collaborators
- Quintiles, Inc.
- Study start
- Jan 2008
- Primary completion
- Jun 2012 (actual)
- Study completion
- Jun 2012 (actual)
- First posted
- 9 Jun 2006 (estimated)
- Results
- Posted 16 Jan 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.
Detailed description
The study was composed of a screening period followed by 3 sequential on-treatment periods, as follows:
- Screening Period (up to 28 days): determination of eligibility and discontinuation of antiparkinsonian disease medications other than levodopa-carbidopa immediate release (LC-oral) prior to nasojejunal (NJ) tube placement.
- NJ Test Period (2 to 14 days): first hospitalization period, Baseline assessments, placement of NJ tube, and optimization of levodopa-carbidopa intestinal gel (LCIG) treatment via NJ tube and infusion pump (participant was hospitalized for NJ tube placement but hospitalization was not required for entire duration of LCIG treatment optimization).
- PEG-J Period (2 to 14 days): second hospitalization period; placement of PEG-J tube; further optimization of LCIG treatment.
- Post PEG-J Long-Term Treatment Period (Day 28 to Day 378): LCIG administration via a permanent PEG-J tube and infusion pump, with dosage adjusted according to clinical condition.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Levodopa-Carbidopa Intestinal Gel (LCIG) | Experimental | Drug: Levodopa-carbidopa intestinal gel, Device: CADD-Legacy® 1400 ambulatory infusion pump, Device: PEG tube, Device: J-tubeAll participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment. The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances. |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
- Levodopa-responsive with severe motor fluctuations
- Recognizable off and on state (motor fluctuations) confirmed by diary
Key exclusion criteria (3 listed)
- Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
- Undergone surgery for the treatment of PD
- Contraindications to levodopa (such as narrow angle glaucoma)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Levodopa-carbidopa intestinal gelInfusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour). | Drug | Levodopa-Carbidopa Intestinal Gel (LCIG) |
| CADD-Legacy® 1400 ambulatory infusion pump | Device | Levodopa-Carbidopa Intestinal Gel (LCIG) |
| PEG tubepercutaneous endoscopic gastrostomy tube | Device | Levodopa-Carbidopa Intestinal Gel (LCIG) |
| J-tubejejunal tube | Device | Levodopa-Carbidopa Intestinal Gel (LCIG) |
Primary outcome
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs
Time frame: Screening through Day 378 + 30 days
AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.
Number of Participants With Device Complications During the Nasojejunal (NJ) Test Period
Time frame: NJ Test Period (from 2 to 14 days)
Complications of the infusion device were collected during the NJ Test period. Pump, intestinal tube, NJ tube, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.
Number of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods
Time frame: PEG-J Surgery Period (from 2 to 14 days) through the Long Term Treatment Period (Day 28 to Day 378)
Complications of the infusion device were collected during the PEG-J Surgery and Post-PEG Long-Term Treatment periods. Pump, PEG-J, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
Time frame: Screening through Day 378
Potentially clinically significant values for red blood cells (RBCs), hemoglobin, and hematocrit are specified for females (f) and males (m) separately in the category rows.
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
Time frame: Screening through Day 378
Terms abbreviated in the table include aspartate aminotransferase (AST), upper limit of normal (ULN), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), female (f), and male (m).
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
Time frame: up to 56 weeks
Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
Time frame: Screening through Day 378
Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.
Number of Participants With Sleep Attacks at Baseline
Time frame: Baseline
To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.
Number of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period
Time frame: During the Post-PEG Long-Term Treatment Period (Day 28 through Day 378)
To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.
Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period
Time frame: Baseline, during the Post-PEG Long-term Treatment Period (Day 28 through Day 378)
The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint
Time frame: Baseline, Endpoint (last Post-PEG Long-Term Period visit up to Day 378)
The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions regarding issues with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia [involuntary muscle movement]).
Number of Participants With Confirmed Cases of Melanoma
Time frame: Screening up to Day 378
A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination or end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.
Number of Participants Taking at Least 1 Concomitant Medication During the Study
Time frame: Screening up to Day 378
Concomitant medications include those started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.
21 secondary outcomes
Change From Baseline in Average Daily "Off" Time at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint
Time frame: Baseline, Endpoint (last post-baseline visit up to Day 378)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 26777085Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14.
- Derived from this study: PubMed 25962554Lew MF, Slevin JT, Kruger R, Martinez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul;21(7):742-8. doi: 10.1016/j.parkreldis.2015.04.022. Epub 2015 Apr 28.
- Derived from this study: PubMed 25545465Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.
- Related InfoLink provided by the sponsor.
Related trials for Advanced Parkinson's Disease
Not yet recruiting
Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.
Parkinson Disease
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
RecruitingPhase 2
Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS
Parkinson's Disease, Deep Brain Stimulation
Not yet recruitingPhase 1
A Phase 1 Study of NCR201 in Parkinson's Disease Patients With Prior DBS
PARKINSON DISEASE (Disorder), Cell Therapy
Active, not recruiting
Enhancing Referral Decision-making for Advanced Treatment in Parkinson's Disease Through Objective Measurements and Patient Reported Outcomes.
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janet Benesh study director
AbbVie
83 sites in 16 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump and PEG tube in people with Advanced Parkinson's Disease, run by AbbVie (prior sponsor, Abbott) at 83 sites in 16 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 83 sites in United States, Germany, Italy, Russia, Czechia and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 16 Jan 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs (time frame: Screening through Day 378 + 30 days). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00335153, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2015.